BiotechTube
Eledon Pharmaceuticals

Eledon Pharmaceuticals

ELDN
United States
eledon.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

ELDN · Stock Price

USD 3.86+0.97 (+33.56%)
Market Cap: $299.5M

Historical price data

Overview

Eledon Pharmaceuticals is a clinical-stage biotech focused on developing tegoprubart, an anti-CD40L antibody, to prevent organ transplant rejection and treat autoimmune/neurodegenerative diseases. Its core strategy is to disrupt the CD40/CD40L costimulatory pathway, potentially offering a safer, more effective alternative to current immunosuppressants. The company has completed a Phase 2 trial (BESTOW) in kidney transplantation and is advancing multiple investigator-sponsored and partnered programs, positioning itself at the forefront of next-generation transplant medicine.

Organ TransplantationAutoimmune DiseasesNeurodegenerative Diseases

Technology Platform

Platform centered on modulating the CD40/CD40L costimulatory pathway using monoclonal antibodies (e.g., tegoprubart) to inhibit immune activation and promote tolerance, with applications in transplant rejection, autoimmunity, and neuroinflammation.

Pipeline

9
9 drugs in pipeline
DrugIndicationStageWatch
AT-1501IgA NephropathyPhase 2
AT-1501Amyotrophic Lateral SclerosisPhase 2
AT-1501 + TacrolimusKidney Transplant RejectionPhase 2
AT-1501Type 1 Diabetes MellitusPhase 2
AT-1501 + TacrolimusKidney Transplant RejectionPhase 2

Opportunities

The primary opportunity is displacing the 30-year-old standard of care in kidney transplantation with a safer, more effective therapy, addressing a multi-billion dollar market.
Additionally, enabling xenotransplantation could position Eledon as a critical player in solving the organ shortage crisis, while applications in autoimmune diseases like Type 1 Diabetes offer significant expansion potential.

Risk Factors

Key risks include clinical failure of tegoprubart in pivotal trials, the challenge of displacing entrenched standard-of-care therapies, and financial runway constraints requiring dilutive or non-dilutive financing in a challenging biotech market.
The company's fate is heavily concentrated on a single asset.

Competitive Landscape

Eledon competes with entrenched calcineurin inhibitors (tacrolimus) and newer agents like belatacept in transplantation. Its differentiation lies in tegoprubart's unique CD40L mechanism and potential safety profile. In xenotransplantation, it holds a first-mover advantage through key partnerships, while in ALS, it faces a crowded field but with a distinct neuroinflammation approach.

More companies in Biologics / Biosimilars →More companies in United States →